Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatme...
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
Research Site, York, United Kingdom
Roswell Park Cancer Institute, Buffalo, New York, United States
Ohio State University, Columbus, Ohio, United States
Norris Comprehensive Cancer Center, Los Angeles, California, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Lowell General Hospital, Lowell, Massachusetts, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Research Site, Caracas, Venezuela
Research Site, Edinburgh, United Kingdom
Montefiore Medical Center, Bronx, New York, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.